“Based on the recent learnings from the positive AURA study at 48 weeks, we intend to use a UPCR of ≤0.5mg/mg and evaluate the primary endpoint at 52 weeks in AURORA,”
So they are essentially keeping the trial the same but with a longer endpoint which is even better as complete remission, or renal response, at 48 weeks was even better than the 24 weeks in the 2b. The trial is even more de-risked.
News 
Market Data 
Discover 
